9/25/2007

The European Commission has approved Novartis AG's Exelon skin patch for the treatment of Alzheimer's disease, the company said. The patch, which was granted FDA approval last July, administers the drug to treat mild to moderate dementia symptoms.

Full Story:
Forbes

Related Summaries